Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment.
Fourteen patients with metastatic malignant melanoma that had failed to respond to standard dacarbazine-based chemotherapy treatment were entered into a phase II study of pegylated liposomal doxorubicin (Caelyx) given as a single intravenous injection at a dose of 50 mg/m(2) at 28 day intervals. No objective responses were documented. Treatment was well tolerated. We conclude that pegylated liposomal doxorubicin does not demonstrate sufficient activity in metastatic melanoma to warrant further investigation in this setting.
Vorobiof
Daniel A
DA
Sandton Oncology Centre, Johannesburg, South Africa. voro@global.co.za
Rapoport
Bernardo L
BL
Mahomed
Rabia
R
Karime
Margaret
M
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008081:Liposomes / Q000378:metabolism*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D011092:Polyethylene Glycols; D004317:Doxorubicin